Japan Considers Approval for iPS Cell Regenerative Medicine Products
Japan's Ministry of Health, Labour and Welfare is reviewing two regenerative medicine products using iPS cells for heart and Parkinson's disease, with a decision expected soon that could lead to the world's first practical application.
Coverage Timeline
Read at source (2 outlets)
iPS細胞の再生医療製品 3月上旬にも製造販売承認見込み 厚労省
19日、国の専門家部会で製造販売が了承された、iPS細胞を使った治療のための2つの再生医療製品について、厚生労働省は、来月上旬にも製造販売を正式に承認する見込みだと発表しました。企業の製造体制や医療機関の準備が整えば、早ければことしの夏ごろにも保険適用による治療が受けられる可能性があるということです。
Read full article →Japan approves world’s first regenerative medicines using iPS cells
Japan’s health ministry panel on Thursday approved the commercialisation of two regenerative medicine products prepared from iPS cells, the first of their kind in the world. The two drugs, ReHeart developed by Cuorips, a start-up originating from the University of Osaka, and Amchepry by Sumitomo Pharma and Racthera, will be used for patients with severe heart failure stemming from ischemic cardiomyopathy and Parkinson’s disease, respectively. “I am very happy to see the first big step towards...
By Kyodo
Read full article →
